Clinical Trials
2 trialsNCT03533361 2018-12-17
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
Eisai Inc.
Approved for marketing
NCT02211222 2016-03-16
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Eisai Inc.
Approved for marketing